Macrogenics To Receive $3M Milestone Payment From Topeka, Initiates Phase 1 Study Of MGD010
March 16, 2015 at 15:27 PM EDT
MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative ...